Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,107 public trials 2,039 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

NCT02569476

Conditions
B-cell Lymphoid Malignancies, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Florida Cancer Specialists Fort Myers Fort Myers, Florida, United States
  • Florida Cancer Specialists East West Palm Beach, Florida, United States
  • Tennessee Oncology Nashville, Tennessee, United States
  • St George Hospital Kogarah, New South Wales, Australia
View all 14 locations
View Trial Details
Completed

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

NCT03955783

Conditions
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Hematologic Diseases, +15 more
Locations
  • Roswell Park Cancer Center Buffalo, New York, United States
  • University Hospitals of Cleveland Cleveland, Ohio, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View all 13 locations
View Trial Details
Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

NCT03520920

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
  • The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

NCT03332173

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Guangdong Provincial Peoples Hospital Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View Trial Details
Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT03206918

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Peking University Peoples Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
View Trial Details
Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Soochow University Branch Shizi Suzhou, Jiangsu, China
View Trial Details
Completed

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

NCT04434937

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Ja-Aichi Anjo Kosei Hospital Anjo, Japan
  • University of Fukui Hospital Fukui, Japan
  • Jcho Kyushu Hospital Fukuoka, Japan
  • National Hospital Organization Kyushu Cancer Center Fukuoka, Japan
View all 30 locations
View Trial Details
Completed

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

NCT03323034

Conditions
Central Nervous System Neoplasms, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Mission Bay San Francisco, California, United States
View all 20 locations
View Trial Details

Related conditions